Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $26.00.

A number of research analysts recently issued reports on SGMT shares. HC Wainwright reissued a “buy” rating and set a $29.00 price target on shares of Sagimet Biosciences in a research report on Wednesday. Barclays assumed coverage on shares of Sagimet Biosciences in a report on Tuesday, January 27th. They issued an “equal weight” rating and a $8.00 price objective on the stock. Guggenheim assumed coverage on shares of Sagimet Biosciences in a report on Tuesday, February 3rd. They set a “buy” rating and a $27.00 target price for the company. Wall Street Zen upgraded shares of Sagimet Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, January 22nd.

Sagimet Biosciences Trading Down 2.4%

Shares of Sagimet Biosciences stock opened at $5.21 on Friday. The firm has a market capitalization of $169.44 million, a P/E ratio of -3.32 and a beta of 3.35. The business has a fifty day simple moving average of $5.73 and a two-hundred day simple moving average of $6.62. Sagimet Biosciences has a 12 month low of $1.73 and a 12 month high of $11.41.

Sagimet Biosciences (NASDAQ:SGMT) last announced its earnings results on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. Analysts predict that Sagimet Biosciences will post -1.6 earnings per share for the current year.

Insider Transactions at Sagimet Biosciences

In other Sagimet Biosciences news, CEO David Happel sold 12,101 shares of Sagimet Biosciences stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total transaction of $64,861.36. Following the completion of the transaction, the chief executive officer owned 677,621 shares in the company, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.70% of the company’s stock.

Hedge Funds Weigh In On Sagimet Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in shares of Sagimet Biosciences in the 4th quarter worth about $62,000. XTX Topco Ltd grew its position in Sagimet Biosciences by 53.6% during the 4th quarter. XTX Topco Ltd now owns 91,737 shares of the company’s stock valued at $543,000 after purchasing an additional 32,003 shares during the last quarter. 683 Capital Management LLC purchased a new stake in Sagimet Biosciences during the 4th quarter valued at about $748,000. Royal Bank of Canada increased its stake in Sagimet Biosciences by 819.2% during the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in Sagimet Biosciences by 141.6% during the 4th quarter. Squarepoint Ops LLC now owns 84,733 shares of the company’s stock valued at $502,000 after purchasing an additional 49,668 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors.

Key Sagimet Biosciences News

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $29 price target, signaling continued bull case from the firm despite the cuts to some forecasts. HC Wainwright Research Note (summary)
• Positive Sentiment: Wall Street Zen published an upgrade on SGMT (reported by American Banking News), providing an additional positive signal from another market source. Sagimet Biosciences Upgraded at Wall Street Zen
• Neutral Sentiment: HC Wainwright slightly raised its FY2028 loss estimate (less negative: from ($3.30) to ($3.22)), a modest improvement but not a turnaround — suggests small model tweaks rather than material fundamental change. HC Wainwright FY2028 revision (summary)
• Negative Sentiment: HC Wainwright reduced several near- and mid‑term EPS forecasts: FY2027 worsened (from ($2.49) to ($2.62)), FY2029 was cut (from ($1.76) to ($1.87)), and quarterly FY2026 estimates were set as negative across Q1–Q4 (around ($0.50)–($0.54) per quarter). These downward revisions increase short‑term uncertainty and likely pressure the stock. HC Wainwright estimates and quarterly guidance (summary)

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.